{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:09Z","timestamp":1788419829464,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Clinical trial evidence is scarce for optimal antiplatelet strategies in patients undergoing intracranial artery stenting with CYP2C19 loss\u2011of\u2011function alleles, especially regarding the efficacy\u2011safety balance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single\u2011center retrospective study enrolled patients receiving genotype\u2011guided antiplatelet regimens for intracranial stenting between January and December 2023, with 6\u2011month follow\u2011up. Clinical outcomes were compared across CYP2C19 phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 205 patients, 46.8% were normal metabolizers, 40.5% intermediate metabolizers, and 12.7% poor metabolizers. Aspirin\u2013clopidogrel was prescribed for all normal metabolizers, 80.7% intermediate metabolizers, and 19.2% poor metabolizers. No intergroup differences were observed in risks of ischemic stroke\/transient ischemic attack (TIA), cardiovascular events, intracerebral hemorrhage (ICH), or any bleeding (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u20050.05). In intermediate metabolizers and poor metabolizer subgroups, ischemic stroke\/TIA rates were 11.1% in the aspirin\u2013clopidogrel group and 9.68% in the aspirin\u2013ticagrelor group, with no significant difference compared to normal metabolizers (4.17%). ICH rates were 1.39% in the aspirin\u2013clopidogrel group and 6.45% in the aspirin\u2013ticagrelor group, showing no significant difference versus normal metabolizers (1.04%). Multivariate logistic analysis found the number of stents (odds ratio [OR]\u2005=\u20052.70; 95% confidence interval [CI]\u2005=\u20050.89\u20136.95;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.043) was a risk factor for ischemic stroke\/TIA. Ticagrelor-based dual antiplatelet therapy (DAPT; OR\u2005=\u200510.57; 95% CI\u2005=\u20051.00\u2013111.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.05) and baseline l ow-density lipoprotein cholesterol (LDL-C; OR\u2005=\u20057.22; 95% CI\u2005=\u20051.80\u201329.01;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.005) were associated with ICH risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antiplatelet regimens were adjusted for a subset of intermediate metabolizers and poor metabolizers prior to stenting, and the 6-month clinical outcomes were comparable across normal metabolizers, intermediate metabolizers, and poor metabolizers. The stent number was associated with ischemic stroke\/TIA risk; baseline LDL-C and ticagrelor-based DAPT with ICH risk. These exploratory findings need validation in adequately powered studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000618","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:00:13Z","timestamp":1788418813000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes stratified by CYP2C19 phenotypes in intracranial artery stenting patients with genotype-guided antiplatelet regimens: a real-world single-center retrospective cohort study"],"prefix":"10.1097","author":[{"given":"Yunzhen","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongde Hospital of Zhejiang Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Information Technology and Artificial Intelligence, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"R1-20260903","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1474-4422(18)30500-3","article-title":"Stroke in China: advances and challenges in epidemiology, prevention, and management.","volume":"18","author":"Wu","year":"2019","journal-title":"Lancet Neurol"},{"key":"R2-20260903","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/STROKEAHA.113.003508","article-title":"Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study.","volume":"45","author":"Wang","year":"2014","journal-title":"Stroke"},{"issue":"1 Suppl","key":"R3-20260903","first-page":"S20","article-title":"Intracranial atherosclerosis: current concepts.","volume":"42","author":"Arenillas","year":"2011","journal-title":"Stroke"},{"key":"R4-20260903","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/STROKEAHA.109.568063","article-title":"In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses: results from the INTRASTENT multicentric registry.","volume":"41","author":"Kurre","year":"2010","journal-title":"Stroke"},{"key":"R5-20260903","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.12000","article-title":"Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial.","volume":"328","author":"Gao","year":"2022","journal-title":"JAMA"},{"key":"R6-20260903","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1212\/WNL.0000000000200030","article-title":"Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory: report of the AAN guideline subcommittee.","volume":"98","author":"Turan","year":"2022","journal-title":"Neurology"},{"key":"R7-20260903","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/0113862073247573230921102631","article-title":"Thromboelastographic and gene polymorphism bimodality detection for dual antiplatelet aggregation therapy in individuals with clopidogrel-resistant symptomatic intracranial artery stenosis.","volume":"27","author":"Liu","year":"2024","journal-title":"Comb Chem High Throughput Screen"},{"key":"R8-20260903","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"key":"R9-20260903","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","article-title":"Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis.","volume":"135","author":"Pan","year":"2017","journal-title":"Circulation"},{"key":"R10-20260903","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update.","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20260903","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA.","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"R12-20260903","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"R13-20260903","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jvs.2018.06.221","article-title":"Influence of multiple stents on periprocedural stroke after carotid artery stenting in the Carotid Revascularization Endarterectomy versus Stent Trial (CREST).","volume":"69","author":"Lal","year":"2019","journal-title":"J Vasc Surg"},{"key":"R14-20260903","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1227\/neu.0000000000002798","article-title":"Residual in-stent carotid stenosis and cigarette smoking are independent predictors of carotid restenosis after carotid artery stenting-results from 738 carotid artery stenting procedures at a single center.","volume":"94","author":"Lai","year":"2024","journal-title":"Neurosurgery"},{"key":"R15-20260903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2021.4514","article-title":"Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.","volume":"79","author":"Lun","year":"2022","journal-title":"JAMA Neurol"},{"key":"R16-20260903","doi-asserted-by":"crossref","first-page":"e207809","DOI":"10.1212\/WNL.0000000000207809","article-title":"One-year outcomes of early therapy with ticagrelor vs clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA trial.","volume":"102","author":"Meng","year":"2024","journal-title":"Neurology"},{"key":"R17-20260903","doi-asserted-by":"crossref","first-page":"108229","DOI":"10.1016\/j.clineuro.2024.108229","article-title":"The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting.","volume":"239","author":"Liu","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"R18-20260903","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1038\/s41598-021-85580-0","article-title":"Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis.","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"R19-20260903","first-page":"100495","article-title":"Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients \u2013 a real life cohort study of two treatment strategies.","volume":"27","author":"Alfredsson","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R20-20260903","doi-asserted-by":"crossref","first-page":"e12978","DOI":"10.1097\/MD.0000000000012978","article-title":"Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: a systematic review and meta-analysis (2007-2017).","volume":"97","author":"Guan","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R21-20260903","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/jnnp-2015-312736","article-title":"Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy).","volume":"87","author":"Pezzini","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R22-20260903","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000007454","article-title":"Lipid levels and the risk of hemorrhagic stroke among women.","volume":"92","author":"Rist","year":"2019","journal-title":"Neurology"},{"key":"R23-20260903","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1212\/WNL.0000000000007853","article-title":"Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study.","volume":"93","author":"Ma","year":"2019","journal-title":"Neurology"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:00:16Z","timestamp":1788418816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000618","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"2026-04-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}